EE154 Budget Impact Analysis of Pembrolizumab Plus Enfortumab Vedotin As First-Line Treatment of Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma in USA
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.457
https://www.valueinhealthjournal.com/article/S1098-3015(23)00557-0/fulltext
Title :
EE154 Budget Impact Analysis of Pembrolizumab Plus Enfortumab Vedotin As First-Line Treatment of Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma in USA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00557-0&doi=10.1016/j.jval.2023.03.457
First page :
Section Title :
Open access? :
No
Section Order :
11844